Hoping to bag the latest Medibank dividend? Read this

Find out all you need to know about the private health insurer's upcoming dividend.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Medibank shares go ex-dividend tomorrow
  • This means they will no longer trade with a dividend attached
  • The dividend of 7.3 cents per share is the highest on record for the company

Time is running out to secure the Medibank Private Ltd (ASX: MPL) dividend.

Because by this time tomorrow, it will have reached its ex-dividend date, which is the time when shares trade without their dividend.

Here are some important details to keep in mind.

A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.

Image source: Getty Images

Medibank dividend

Medibank offers investors an interim dividend of 7.3 cents per share. It's fully franked too, so it carries certain tax benefits.

The dividend is payable on 29 September and has a trailing dividend yield of 3.7%.

You must hold Medibank shares before the ex-dividend date to receive the dividend.

Zooming out a little, we see that 7.3 cents per share is the highest dividend the company has ever offered investors in its dividend history, stretching back to 2015.

As my Fool colleague Cathryn pointed out, this is likely due to the company seeing a 9% boost in its net profit after tax (NPAT) for FY22 and, thus, being able to distribute higher profits to investors.

Medibank share price snapshot

Shares of Medibank currently trade for $3.655 each, up 0.69% on yesterday's closing price of $3.63.

The Medibank share price is up 9.25% year to date. Meanwhile, the S&P/ASX 200 Index (ASX: XJO) is down around 8% over the same period.

The company's current market capitalisation is approximately $10 billion.

Motley Fool contributor Matthew Farley has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Up 31% in a month, why are Telix shares lifting off again on Friday?

ASX investors are piling into Telix shares today. But why?

Read more »

Doctor checking patient's spine x-ray image.
Healthcare Shares

Where is the value amongst ASX healthcare shares?

These three stocks are worth monitoring.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Telix Pharmaceuticals: FDA accepts Pixclara NDA

The FDA has accepted Telix's Pixclara NDA for imaging brain cancer.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Bell Potter says this ASX healthcare stock could rise nearly 200%

The positive announcement has reinforced the broker's recommendation.

Read more »

A man rests his chin in his hands, pondering what is the answer?
Healthcare Shares

CSL shares: 3 reasons to buy and 3 reasons to sell

CSL shares have tumbled again.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Broker Notes

What's Bell Potter's updated view on CSL shares?

Will the new tariffs impact CSL according to Bell Potter?

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Are Cogsgate shares a buy, hold or sell after rocketing 12% higher yesterday?

This broker thinks there could be more growth to come.

Read more »

woman in lab coat conducting testing.
Healthcare Shares

Is this battered ASX biotech stock ready to rocket higher?

Brokers are upbeat and see upside of up to 125%!

Read more »